Article
Oncology
Dong-Dong Jia, Yanling Niu, Honglin Zhu, Sizhen Wang, Tonghui Ma, Tao Li
Summary: This study investigated the impact of prior IFN-alpha therapy on subsequent PD-1 blockade in melanoma patients. The findings showed that prior PEG-IFN-alpha therapy enhanced the efficacy of adjuvant pembrolizumab, reducing recurrence rates and prolonging recurrence-free survival. These results suggest that prior PEG-IFN-alpha treatment could be beneficial in designing combination or sequential immunotherapy for melanoma patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Infectious Diseases
Anuja Pandit, Nirav Bhalani, B. L. Shashi Bhushan, Parshottam Koradia, Shweta Gargiya, Vinay Bhomia, Kevinkumar Kansagra
Summary: The study evaluated the efficacy and safety of PEG IFN-α2b with SOC in treating moderate COVID-19, showing a significant clinical improvement on day 15 likely due to faster viral reduction compared to SOC. Subjects in the PEG IFN-α2b plus SOC group had a higher rate of negative RT-PCR results on day 7 and day 14 compared to the SOC group.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Biochemical Research Methods
Manoj Bob Kusuma, Ravisekhar Kashibhatta, Sandeep S. Jagtap, Vijay Nadawade, Suresh Adsul, Sudheer Moorkoth, Krishnamurthy Bhat, Rustom Mody, Praveen Vithala
Summary: A sensitive method using LC-MS/MS was developed for the determination of PEG-IFN-alpha-2b in human serum, which showed bioequivalence in a clinical study. The method demonstrated high sensitivity, precision, and accuracy, making it a promising approach for estimating PEG-IFN-alpha-2b and potentially other pegylated molecules.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
(2021)
Review
Rheumatology
Nicolas Jimenez-Garcia, Josefa Aguilar-Garcia, Ines Fernandez-Canedo, Nuria Blazquez-Sanchez, Rafael Funez-Liebana, Carlos Romero-Gomez
Summary: Eosinophilic fasciitis (EF) is a rare disease characterized by skin hardening and prominent hair follicles. This case study reports a pregnant woman diagnosed with EF during pregnancy, with complex treatment but favorable progression. Other cases of EF in pregnant women have also shown positive response to steroid treatment.
RHEUMATOLOGY INTERNATIONAL
(2021)
Article
Pediatrics
Celine Habre, Alexia Dabadie, Anderson D. Loundou, Jean-Bruno Banos, Catherine Desvignes, Harmony Pico, Audrey Aschero, Nathalie Colavolpe, Charlotte Seiler, Corinne Bouvier, Emilie Peltier, Jean-Claude Gentet, Christiane Baunin, Pascal Auquier, Philippe Petit
Summary: DWI in mid-course preoperative chemotherapy for osteosarcoma shows potential for evaluating histological necrosis and predicting survival. Anticipating response to neoadjuvant treatment by DWI may have implications for preoperative management.
PEDIATRIC RADIOLOGY
(2021)
Article
Oncology
Amine Bouhamama, Benjamin Leporq, Wassef Khaled, Angeline Nemeth, Mehdi Brahmi, Julie Dufau, Perrine Marec-Berard, Jean-Luc Drape, Francois Gouin, Axelle Bertrand-Vasseur, Jean-Yves Blay, Olivier Beuf, Frank Pilleul
Summary: An MRI-based radiomics model can predict the response of osteosarcoma patients to neoadjuvant chemotherapy, which is crucial for guiding treatment and improving survival rates.
RADIOLOGY-IMAGING CANCER
(2022)
Article
Orthopedics
Lawrence M. White, Angela Atinga, Ali M. Naraghi, Katherine Lajkosz, Jay S. Wunder, Peter Ferguson, Kim Tsoi, Anthony Griffin, Masoom Haider
Summary: This study analyzed radiomic features extracted from pre-treatment T2-weighted MRI scans to predict tumor necrosis, overall survival, and disease-free survival in patients with high-grade intramedullary osteosarcoma. The results showed that radiomic models have potential as prognostic biomarkers for predicting tumor response to neoadjuvant chemotherapy and clinical outcomes in conventional osteosarcoma.
SKELETAL RADIOLOGY
(2023)
Article
Rheumatology
Satoshi Muto, Nana Minamitani, Takehisa Ogura, Arata Nakajima, Koichi Nakagawa, Toru Masaka, Sumiko Hiura, Hideki Kobayashi, Hiroyoshi Kato, Hideto Kameda
Summary: This study investigated the association between clinical response to MTX and ABCG2 gene expression in MTX-naive patients with RA. Results showed that good responders had a decrease in ABCG2 expression after 12 weeks of MTX treatment, while non-good responders did not show this decrease. The study suggests that a decrease in ABCG2 expression may be associated with a good response to MTX in RA patients.
MODERN RHEUMATOLOGY
(2021)
Article
Pediatrics
Amaranto Suarez-Mattos, Federico Arroyave, Ana M. Infante, Carlos Narvaez, Camilo Soto, Luis Gomez, Javier Amaya-Nieto
Summary: This study evaluated the histologic response to neoadjuvant chemotherapy and overall and event-free survival rates in patients under 21 years old with conventional osteosarcoma. Good responders showed improved overall and event-free survival rates.
BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO
(2022)
Article
Oncology
Jumoke Okikiolu, Claire Woodley, Llywelyn Cadman-Davies, Jennifer O'Sullivan, Deepti Radia, Natalia Curto Garcia, Patrick Harrington, Shahram Kordasti, Susan Asirvatham, Priya Sriskandarajah, Jamie Saunders, Chandan Saha, Irene Sanchez, Hugues deLavallade, Donal P. McLornan, Claire N. Harrison
Summary: Ropeginterferon alfa-2b (ropegIFN) has been recommended by EMA for the treatment of PV and received FDA approval in November 2021. We demonstrate the safety and tolerability of ropegIFN in a series of MPN patients at different doses, supporting its efficacy in PV patients and use in pregnancy.
LEUKEMIA RESEARCH REPORTS
(2023)
Article
Medicine, Research & Experimental
Thianti Sylviningrum, Ismiralda Oke Putranti, Octavia Permata Sari, Fitranto Arjadi, Triasari Oktavriana
Summary: The study found an association between HLA-Cw6 allele expression and treatment response to NB-UVB in Javanese-Indonesian psoriasis subjects, especially in female patients without comorbid diseases. However, no significant association was found between HLA-Cw6 allele expression and treatment response to MTX.
INDONESIAN BIOMEDICAL JOURNAL
(2021)
Article
Oncology
Yogi Prabowo, Iwan Setiawan, Achmad Fauzi Kamal, Evelina Kodrat, Muhammad Luqman Labib Zufar
Summary: Age, gender, symptom duration, and tumor size after neoadjuvant chemotherapy are significant prognostic factors affecting the histopathological response to neoadjuvant chemotherapy in patients with osteosarcoma.
INTERNATIONAL JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
Clemens M. Meier, Joerg Fuchs, Dietrich von Schweinitz, Raimund Stein, Stefan Wagenpfeil, Leo Kager, Jens-Peter Schenk, Christian Vokuhl, Patrick Melchior, Nils Welter, Rhoikos Furtwaengler, Norbert Graf
Summary: This study aims to identify factors associated with the occurrence of local relapse (LR) after treatment for unilateral nephroblastoma. Retrospective analysis of 2386 patients showed that age, tumor volume, histology, and extent of lymph node removal were significant risk factors for LR. Local relapse is associated with an increased risk of death, but surgical intervention can reduce relapse and improve patient outcomes.
Article
Oncology
Stefanie Hecker-Nolting, Daniel Baumhoer, Claudia Blattmann, Leo Kager, Thomas Kuehne, Matthias Kevric, Susanna Lang, Vanessa Mettmann, Benjamin Sorg, Matthias Werner, Stefan S. Bielack
Summary: This study aims to investigate the characteristics and survival outcomes of osteosarcoma patients who were initially treated assuming a different tumor diagnosis. The study found that some osteosarcoma patients may initially be misdiagnosed, leading to inappropriate treatment. However, once correctly diagnosed, these patients still have the potential to be cured through modern osteosarcoma treatment standards.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Justin Oh, Paulina Gutkin, Yi Peng Wang, Navjot Sandhu, Robbie G. Majzner, Helen Nadel, Hiroyuki Shimada, Olivia Lansinger, Rie von Eyben, Sarah Donaldson, Matias Bruzoni, Quaovi H. Sodji, Susan M. Hiniker
Summary: This study aimed to determine the resolution time of I-123-MIBG avidity after radiation therapy (RT) in neuroblastoma (NB) and the rate of local failure (LF). The median time to resolution of I-123-MIBG activity after RT was found to be 78 days. Primary lesions without residual disease showed excellent local control, while the LF rate was higher after RT for residual disease and there was no benefit observed for boost RT.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY
(2023)
Article
Oncology
Kevin B. Cederberg, Ramesh S. Iyer, Apeksha Chaturvedi, M. B. McCarville, Janice D. McDaniel, Jesse K. Sandberg, Amer Shammas, Susan E. Sharp, Helen R. Nadel
Summary: This paper provides consensus-based recommendations for imaging in children with osteosarcoma and Ewing sarcoma at diagnosis, during therapy, and after therapy.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Oncology
Paul Meyers, Emily Slotkin
Summary: This study reviewed the use of irinotecan and temozolomide in patients with recurrent Ewing sarcoma. The results showed that a 10-day irinotecan treatment schedule had a higher objective response rate compared to a 5-day schedule. Therefore, the use of a 10-day irinotecan schedule should be considered in the treatment of recurrent Ewing sarcoma.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Oncology
Joyce Mhlanga, Adina Alazraki, Steve Cho, Hollie Lai, Helen Nadel, Neeta Pandit-Taskar, Jing Qi, Dhanashree Rajderkar, Stephan Voss, Pankaj Watal, Kathleen McCarten
Summary: This paper provides consensus-based imaging recommendations for evaluation and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) at diagnosis and throughout the therapy.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Pathology
David J. Ho, Narasimhan P. Agaram, Stephanie D. Suser, Cynthia Chu, Chad M. Vanderbilt, Paul A. Meyers, Leonard H. Wexler, John H. Healey, Thomas J. Fuchs, Meera R. Hameed
Summary: In this study, a deep learning-based approach was proposed to estimate necrosis ratio and predict treatment response and patient outcome in osteosarcoma. The results demonstrate that deep learning can serve as an objective tool for pathologists to analyze histology, assess treatment response, and predict patient prognosis.
AMERICAN JOURNAL OF PATHOLOGY
(2023)
Letter
Pharmacology & Pharmacy
Mirjam de With, Jonathan Knikman, Jan H. M. Schellens, Hans Gelderblom, Annemieke Cats, Henk-Jan Guchelaar, Ron H. J. Mathijssen, Jesse J. Swen, Didier Meulendijks
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Oncology
Nicole Bodmer, Stefanie Hecker-Nolting, Godehard Friedel, Claudia Blattmann, Leo Kager, Torsten Kessler, Matthias Kevric Dok, Thomas Kuhne, Vanessa Mettmann, Peter Mueller-Abt, Benjamin Sorg, Matthias Theobald, Stefan S. Bielack
Summary: This study analyzed the clinical characteristics and optimal therapeutic strategies for primary rib osteosarcoma. The results showed that surgery and chemotherapy played a key role in treatment, but negative prognostic factors included incomplete tumor surgery, osteoblastic histology, and poor response to chemotherapy. Early diagnosis and effective local control are crucial for better outcomes.
Article
Medicine, Research & Experimental
Adam D. N. Williams, Gwyneth Davies, Amanda J. Farrin, Marion Mafham, Michael Robling, Matthew R. Sydes, Fiona V. Lugg-Widger
Summary: This study aimed to identify the ongoing challenges of using routinely collected data in clinical trials through anonymous surveys and consensus meetings with key stakeholders. The study resulted in a prioritized list of seven questions that should guide future research efforts and ensure the benefits of infrastructure for routinely collected data are achieved.
Article
Oncology
William D. Tap, Maitreyi G. Sharma, Marc Vallee, Bryan D. Smith, Matthew L. Sherman, Rodrigo Ruiz-Soto, Michiel van de Sande, R. Lor Randall, Nicholas M. Bernthal, Hans Gelderblom
Summary: TGCT is a rare neoplasm caused by upregulation of the CSF1 gene. Vimseltinib, an oral tyrosine kinase inhibitor, is being tested in the Phase III MOTION trial for its efficacy and safety in TGCT patients who are not suitable for surgery. Participants will receive vimseltinib or placebo in Part 1, followed by open-label vimseltinib treatment in Part 2.
Article
Medicine, General & Internal
Adrian Sacher, Patricia LoRusso, Manish R. Patel, Wilson H. Miller, Elena Garralda, Martin D. Forster, Armando Santoro, Alejandro Falcon, Tae Won Kim, Luis Paz-Ares, Samantha Bowyer, Maria de Miguel, Sae-Won Han, Matthew G. Krebs, Jong-Seok Lee, Michael L. Cheng, Kathryn Arbour, Erminia Massarelli, Yoonha Choi, Zhen Shi, Sandhya Mandlekar, Mark T. Lin, Stephanie Royer-Joo, Julie Chang, Neekesh V. Dharia, Jennifer L. Schutzman, Jayesh Desai
Summary: Divarasib, a KRAS G12C inhibitor, has shown promising therapeutic effects with minimal adverse events in patients with tumors harboring the KRAS G12C mutation.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, Research & Experimental
Martin Law, Dominique-Laurent Couturier, Babak Choodari-Oskooei, Phillip Crout, Carrol Gamble, Peter Jacko, Philip Pallmann, Mark Pilling, David S. Robertson, Michael Robling, Matthew R. Sydes, Sofia S. Villar, James Wason, Graham Wheeler, S. Faye Williamson, Christina Yap, Thomas Jaki
Summary: The UK Medicines and Healthcare products Regulatory Agency sought opinions on proposals to improve and strengthen clinical trials legislation, highlighting the issues of reliance on legislation and the absence of data sharing. The discussion raised concerns about the potential negative impact of legislation on adaptive design clinical trials. Data sharing, as part of open science and reproducible research, was emphasized as increasingly important for clinical trials.
Article
Medicine, Research & Experimental
E. J. Mitchell, D. Appelbe, A. Bravery, L. Culliford, H. Evans, A. J. Farrin, K. Gillies, K. Hood, S. B. Love, M. R. Sydes, P. R. Williamson, N. Wakefield, e Consent collaborative Grp
Summary: During the COVID-19 pandemic, there has been an increase in the use of e-Consent in academic-led clinical trials. However, there are still uncertainties among trialists, patients, and the public regarding its implementation, including a lack of formal guidance and evidence for optimal and appropriate methods.
Article
Oncology
Josephine Kersting, Andreas Ranft, Vivek Bhadri, Benedicte Brichard, Stephane Collaud, Sona Cyprova, Hans Eich, Torben Ek, Hans Gelderblom, Jendrik Hardes, Lianne Haveman, Wolfgang Hartmann, Peter Hauser, Philip Heesen, Heribert Juergens, Jukka Kanerva, Thomas Kuehne, Anna Raciborska, Jelena Rascon, Victor Rechl, Arne Streitbuerger, Beate Timmermann, Yasmine Uhlenbruch, Uta Dirksen
Summary: This study analyzed the effect of different radiation therapy (RT) doses on event-free survival (EFS) and overall survival (OS) in patients with Ewing sarcoma (EwS). It was found that higher RT dose in the combined local therapy modality had an impact on EFS, while higher dose of radiation in definitive RT was associated with increased OS. The study identified indications for selection biases for dosage and called for randomized trials to assess the value of different RT doses.
ADVANCES IN RADIATION ONCOLOGY
(2023)